Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720

Blood

Volumn 100, Issue 4, 2002, Pages 1224-1232

  Baer, Maria R ^{a,b,c,d,e,f,g}   George, Stephen L ^{a,b,c,d,e,f,g}   Dodge, Richard K ^{a,b,c,d,e,f,g}   O'Loughlin, Kieran L ^{a,b,c,d,e,f,g}   Minderman, Hans ^{a,b,c,d,e,f,g}   Caligiuri, Michael A ^{a,b,c,d,e,f,g}   Anastasi, John ^{a,b,c,d,e,f,g}   Powell, Bayard L ^{a,b,c,d,e,f,g}   Kolitz, Jonathan E ^{a,b,c,d,e,f,g}   Schiffer, Charles A ^{a,b,c,d,e,f,g}   Bloomfield, Clara D ^{a,b,c,d,e,f,g}   Larson, Richard A ^{a,b,c,d,e,f,g}  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CALGB Statistical Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; INTERLEUKIN 2; MULTIDRUG RESISTANCE PROTEIN; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DRUG TRANSPORT; DYSPNEA; ESOPHAGITIS; FEMALE; GENETIC CODE; HEART EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; INFECTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALAISE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; TRANSPORT KINETICS; TREATMENT OUTCOME;

EID: 0037103189     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.4.1224.h81602001224_1224_1232     Document Type: Article

References (54)

1. Intensive postremission chemotherapy in adults with acute myeloid leukemia
2. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia
3. A randomized placebo-controlled phase 3 study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
4. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)
5. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031)
6. Acute myeloid leukemia in the elderly: Assessment of multi-drug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study
7. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia
8. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study
9. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
10. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia
11. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo
12. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity
13. Parallel phase 1 studies of daunorubicin given with cytosine arabinoside and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients ≥60 years of age with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420
14. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American -British Group
15. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)
16. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
17. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interieukin-2 plus periodic intermediate-dose pulsing
18. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
19. A successful system of scientific data audits for clinical trials: A report from the Cancer and Leukemia Group B
20. Report of the National Cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
21. Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: Results from CALGB 8461
22. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1 +/efflux- cases
23. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeleid leukemia: A Southwest Oncology Group Study
24. A phase 1 study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC-833: A Southwest Oncology Group study 9617
25. 2(3) is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux
26. Proof without prejudice: Use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources
27. Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein
28. A network algorithm for performing Fisher's exact test in r × c contingency tables
29. Nonparametric estimation from incomplete observations
30. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples
31. A phase 1 trial of doxorubicin (D) and PSC833: A modulator of multidrug resistance (MDR)
32. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase 1 study
33. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors
34. Phase 1 study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
35. Phase 1 study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
36. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
37. Dose-finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ara-C in untreated elderly patients with acute myeloid leukemia
38. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
39. Phase 1/2 study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
40. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs. MEC: Randomized phase 3 trial (E2995)
41. Phase 1/2 trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
42. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study
43. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial
44. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group pilot study
45. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
46. P-glycoprotein plays a drug efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway
47. Novel mechanisms of drug resistance in leukemia
48. Phase 1 and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin
49. Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein
50. Etoposide in acute nonlymphocytic leukemia
51. Parallel phase 1 trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) < 60 years old: Preliminary results of CALGB 9621